Disease · MONDO_0003199
anal carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. anal carcinoma. Diseases, record MONDO_0003199. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003199
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MITOMYCIN | CHEMBL105 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BINTRAFUSP ALFA | CHEMBL4298024 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CAPECITABINE | CHEMBL1773 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets33
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CD274 | Programmed cell death 1 ligand 1 | 4 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 3 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 2 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| TYMS | Thymidylate synthase | 2 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 2 | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor | Phase 2 | https://conductscience.org/library/genes/613 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/8451 | Drugs and targets |
| DDB1 | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 1 | https://conductscience.org/library/genes/1642 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 1 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
1 to 10 of 33
See all 33 targetsTrials32
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | Phase 1/2 | 224 | 2026-03-09 | Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | Phase 1/2 | 143 | 2025-12-02 | HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma | AVELUMAB, TIPAPKINOGENE SOVACIVEC | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00316888 | Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer | Phase 2 | 63 | 2016-08-29 | Anal Cancer | CETUXIMAB, CISPLATIN, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
| NCT03427411 | M7824 in Subjects With HPV Associated Malignancies | Phase 2 | 57 | 2022-02-28 | Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer, Vaginal or Penile Cancer | BINTRAFUSP ALFA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | Phase 1/2 | 51 | 2023-11-18 | Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | BINTRAFUSP ALFA, IMMUNOCYTOKINE NHS-IL12, PEXIPEPIMUT-S | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00324415 | Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer | Phase 2 | 45 | 2015-09-17 | Anal Cancer | CETUXIMAB, CISPLATIN, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
| NCT00941889 | The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata | Not applicable | 32 | 2016-07-25 | HIV Positive, Anal Condylomata, Anal Warts, HIV Infections | HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01585428 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | Phase 2 | 29 | 2017-03-23 | Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | Phase 1/2 | 12 | 2017-08-02 | Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer | ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | Phase 1/2 | 11 | 2024-01-11 | Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus | CYCLOPHOSPHAMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 32
See all 32 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Closed to Accrual as of 11/3/2008) vs Arm II (Open to Accrual on 8/18/2009): serious adverse events | 26 of 28 | 29 of 34 | 62 | NCT00316888 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 30 of 30 | 26 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: Number of Participants With Serious Grade ≥3 Adverse Events Considered Related to Study Treatment of M7824 | 6 of 30 | 4 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: deaths from any cause | 18 of 30 | 22 of 26 | 56 | NCT03427411 | Trial comparisons |
Participants Naïve to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks vs Participants Refractory to Checkpoint Inhibition - M7824 1,200 mg Intravenous Once Every 2 Weeks: serious adverse events | 19 of 30 | 21 of 26 | 56 | NCT03427411 | Trial comparisons |
Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 47 of 47 | 3 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: deaths from any cause | 28 of 47 | 0 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies vs Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy: serious adverse events | 18 of 47 | 1 of 3 | 50 | NCT04287868 | Trial comparisons |
| Cervical vs NonCervical: Number of Patients With Serious and Non-serious Adverse Events | 18 of 18 | 11 of 11 | 29 | NCT01585428 | Trial comparisons |
| Cervical vs NonCervical: deaths from any cause | 1 of 18 | 0 of 11 | 29 | NCT01585428 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003199
GET https://conductscience.org/api/diseases/v1/MONDO_0003199/drugs?page=2